List of works - Suzan M Hammond

Correlating In Vitro Splice Switching Activity With Systemic In Vivo Delivery Using Novel ZEN-modified Oligonucleotides.

scientific article published on 25 November 2014

Design and application of bispecific splice-switching oligonucleotides

scientific article published on February 2014

Genetic therapies for RNA mis-splicing diseases ⬇️

scientific article (publication date: May 2011)

How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse

scientific article published in May 2015

Identification of a Peptide for Systemic Brain Delivery of a Morpholino Oligonucleotide in Mouse Models of Spinal Muscular Atrophy

scientific article

Implications for Cardiac Function Following Rescue of the Dystrophic Diaphragm in a Mouse Model of Duchenne Muscular Dystrophy.

scientific article published on 26 June 2015

Interventions Targeting Glucocorticoid-Krüppel-like Factor 15-Branched-Chain Amino Acid Signaling Improve Disease Phenotypes in Spinal Muscular Atrophy Mice.

scientific article

Molecular and phenotypic reassessment of an infrequently used mouse model for spinal muscular atrophy.

scientific article published on 4 December 2009

Mouse survival motor neuron alleles that mimic SMN2 splicing and are inducible rescue embryonic lethality early in development but not late

scientific article

Negative regulatory elements are present in the human LMO2 oncogene and may contribute to its expression in leukemia.

scientific article published in January 2005

Optimizing Tissue-Specific Antisense Oligonucleotide–Peptide Conjugates ⬇️

scientific article published on January 1, 2012

PRO-051, an antisense oligonucleotide for the potential treatment of Duchenne muscular dystrophy.

scientific article

Peptide nanoparticle delivery of charge-neutral splice-switching morpholino oligonucleotides.

scientific article published on 16 January 2015

Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice.

scientific article

Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment.

scientific article published on 14 August 2012

Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice

scientific article

Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy

scientific article

Targeting the 5' untranslated region of <i>SMN2</i> as a therapeutic strategy for spinal muscular atrophy

scientific article published on 05 January 2021

Transfer of genetic therapy across human populations: molecular targets for increasing patient coverage in repeat expansion diseases.

scientific article published on 20 May 2015

Use of cell-penetrating-peptides in oligonucleotide splice switching therapy.

scientific article published on June 2012

List of works by Suzan M Hammond

Correlating In Vitro Splice Switching Activity With Systemic In Vivo Delivery Using Novel ZEN-modified Oligonucleotides.

Design and application of bispecific splice-switching oligonucleotides

Genetic therapies for RNA mis-splicing diseases ⬇️

How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse

Identification of a Peptide for Systemic Brain Delivery of a Morpholino Oligonucleotide in Mouse Models of Spinal Muscular Atrophy

Implications for Cardiac Function Following Rescue of the Dystrophic Diaphragm in a Mouse Model of Duchenne Muscular Dystrophy.

Interventions Targeting Glucocorticoid-Krüppel-like Factor 15-Branched-Chain Amino Acid Signaling Improve Disease Phenotypes in Spinal Muscular Atrophy Mice.

Molecular and phenotypic reassessment of an infrequently used mouse model for spinal muscular atrophy.

Mouse survival motor neuron alleles that mimic SMN2 splicing and are inducible rescue embryonic lethality early in development but not late

Negative regulatory elements are present in the human LMO2 oncogene and may contribute to its expression in leukemia.

Optimizing Tissue-Specific Antisense Oligonucleotide–Peptide Conjugates ⬇️

PRO-051, an antisense oligonucleotide for the potential treatment of Duchenne muscular dystrophy.

Peptide nanoparticle delivery of charge-neutral splice-switching morpholino oligonucleotides.

Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice.

Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment.

Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice

Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy

Targeting the 5' untranslated region of <i>SMN2</i> as a therapeutic strategy for spinal muscular atrophy

Transfer of genetic therapy across human populations: molecular targets for increasing patient coverage in repeat expansion diseases.

Use of cell-penetrating-peptides in oligonucleotide splice switching therapy.